Preoperative chemoradiation with UFT-E plue leucovorin and translational study for locally advanced rectal cancer
| ISRCTN | ISRCTN11812525 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11812525 |
| Secondary identifying numbers | NCC-CTS-08-358 |
- Submission date
- 05/07/2016
- Registration date
- 25/07/2016
- Last edited
- 20/10/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English Summary
Background and study aims
Rectal cancer is a type of cancer that develops in the large bowel. I’ts called rectal cancer because of its position within the length of the bowel. Patients that have been diagnosed with locally advanced rectal cancer (that is, cancer that has grown through the wall of the rectum but not yet spread to the lymph nodes) are often treated with both chemotherapy and radiation (chemoradiation) before they considered for surgery. This study is investigating the success of a particular treatment; namely a high-dose of a drug called tegafur-uracil together with another one called leucovorin in addition to radiation therapy for patients before they undergo surgery for locally advanced rectal cancer.
Who can participate?
Adults with locally advanced rectal cancer that have not yet been treated with chemotherapy.
What does the study involve?
All participants are given radiotherapy plus chemotherapy treatment with tegafur-uracil (400mg/m2/day) and leucovorin (90mg/day). The drugs are given to each patient throughout their radiation treatment. All participants are then followed up to see whether their cancer has responded to the treatment, whether they suffered any ill effects from the treatment, how long it is before the cancer reoccurs. Overall survival rate data is also collected. Participants are also asked to give blood samples for pharmacogenetic analysis to see whether people with certain genetic profiles are more likely to be successfully treated than others.
What are the possible benefits and risks of participating?
Participants are given the treatment without change for the duration of the study. There could be some adverse effects from taking the high dose of tegafur-uracil.
Where is the study run from?
National Cancer Center, Goyang (South Korea)
When is the study starting and how long is it expected to run for?
October 2008 to November 2012
Who is funding the study?
National Cancer Center, Goyang (South Korea)
Who is the main contact?
Ms Hyun Mi Kim
ncccolonco@hanmail.net
Contact information
Scientific
323 Ilsan-ro, Ilsandong-gu
Goyang
10408
Korea, South
| Phone | 82-31-920-1145 |
|---|---|
| ncccolonco@hanmail.net |
Study information
| Study design | Single-arm phase II study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | No participant information sheet available |
| Scientific title | A phase II study of preoperative chemoradiation with UFT-E plus leucovorin and the translational research for detection of predictive markers in the patients with locally advanced resectable rectal cancer |
| Study hypothesis | Pathologic complete response rate with enteric coated tegafur-uracil(UFT-E) and leucovorin for locally advanced rectal cancer (cT3-4NxM0) would be more than 20% |
| Ethics approval(s) | Institutional Review Boards of National Cancer Center, Korea, 20/10/2008, ref: NCCCTS-08-358 |
| Condition | Locally advanced rectal cancer (cT3-4, Nx, M0) |
| Intervention | This is a single-arm, phase II study of preoperative radiotherapy (RT) with enteric-coated tegafur-uracil (UFT-E) and leucovorin. 1. Radiotherapy (RT): started within 14 days after screening and obtaining informed consent. RT to whole pelvis at a dose of 45 Gy in 25 fractions, followed by 5.4 Gy in a three-fraction boost to the primary tumor. 2. Enteric-coated tegafur-uracil (UFT-E) : 400 mg/m2 of tegafur divided into three daily doses without drug holidays during RT. - Since each package of UFT-E contains 500 mg of granules that correspons to 100 mg of tegafur, the recommended dosing schedule according to body surface area (BSA) are as follows: 2.1. BSA ≤ 1.37 m2: 2, 2, and 1 packages an hour after breakfast, lunch and dinner, respectively 2.2. BSA 1.38 m2 – 1.62 m2: 2, 2, and 2 packages; BSA 1.63 m2 – 1.87 m2: 3, 2, and 2 packages 2.3. BSA ³ 1.88 m2: 3, 3, and 2 packages 3. Leucovorin: 30mg (2 tablets) p.o. With each UFF-E dose, corresponding to a total daily dose of 90 mg 4. Surgery: planned within 6 ± 2 weeks of the completion of RT. Total mesorectal excision is the first-choice surgical treatment |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase II |
| Drug / device / biological / vaccine name(s) | 1. Enteric-coated tefagur-uracil 2. Leucovorin |
| Primary outcome measure | Pathologic complete response by Dworak’s classification, assessed with surgical specimen (including primary tumor and regional lymph nodes) derived from total mesorectal excision. Dworak’s classification: Grade 0 no regression Grade 1 dominant tumor mass with obvious fibrosis and/or vasculopathy Grade 2 dominantly fibrotic changes with few tumor cells or groups (easy to find) Grade 3 very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance Grade 4 no tumor cells, only fibrotic mass (total regression or response) |
| Secondary outcome measures | 1. Safety: measured with National Cancer Institute Common Terminology Criteria (NCI-CTC) scale, version 3.0 2. Relapse-free survival : the time from the date of starting CRT to the date on which either of recurrence, progression, or death was first observed, or the date of last follow-up 3. Overall survival: the time from the date of starting CRT to the date of death from any cause or last follow-up 4. Pharmacogenetic analysis: genomic DNA from peripheral blood will be analyzed for the following polymorphism: CYP2A6*4 (whole deletion of CYP2A6), CYP2A6*7 (6558T>G, rs5031016), CYP2A6*9 (-48T>G, rs28399433), CYP2A6*10 (6558T>C and 6600G>T, rs28399468), UMPS 638G>C (rs1801019), ABCB1 3545 C>T (rs1045642), ABCB1 1236 C>T (rs1128503), and ABCB1 2677 G>T/A (rs2032582) |
| Overall study start date | 20/10/2008 |
| Overall study end date | 30/11/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 121 |
| Participant inclusion criteria | 1. Histologically diagnosed adenocarcinoma of rectum 2. Located within 8cm from anal verge 3. cT3/4 by rectal MRI+/- endorectal ultrasound 4. 18 years old or more 5. ECOG performance status <=2 6. No previous chemotherapy 7. No previous radiotherapy to pelvis 8. Adequate bone marrow, hepatic, and renal function |
| Participant exclusion criteria | 1. Rectal cancer of histology other than adenocarcinoma 2. Adenocarcinoma developed from inflammatory bowel disease 3. Presence of distant metastases 4. Existence of unresected synchronous colon cancer 5. Unresolved bowel obstruction 6. Clinically unresectable disease 7. Uncontrolled cardiovascular disease 8. Uncontrolled active infection 9. History of other malignancies within 5 years from screening 10. History of organ transplantation that necessitates immunosuppressive treatment 11. Uncontrolled epileptic disease or psychiatric disease 12. Pregnant or breastfeeding women, or women with child-bearing potential who are not compliant to 13. Contraception policy of this study |
| Recruitment start date | 09/01/2009 |
| Recruitment end date | 28/08/2012 |
Locations
Countries of recruitment
- Korea, South
Study participating centre
Goyang
10408
Korea, South
Sponsor information
Hospital/treatment centre
323 Ilsan-ro, Ilsandong-gu
Goyang
10408
Korea, South
"ROR" |
https://ror.org/02tsanh21 |
|---|
Funders
Funder type
Not defined
Government organisation / National government
- Alternative name(s)
- NCC
- Location
- Korea, South
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 27/03/2017 | Yes | No |
Editorial Notes
20/10/2017: Publication reference added.
